All cell lines used in this study were purchased from ATCC (Manassas, VA, USA). HeLa, U-2 OS, HEK293, HCT 116, and HepG2 cells were grown in DMEM (Welgene, Gyeongsan, Korea) supplemented with 10% FBS (Gibco, Waltham, MA, USA) and 1% penicillin/streptomycin (Corning, NY, USA). SK-N-SH cells were cultured in RPMI (Corning) supplemented with 10% FBS and 1% penicillin/streptomycin.
All sequence-specific oligonucleotides (SSOs) were purchased from Bioneer (Daejeon, Korea). The SSOs were synthesized with 2′-O-methyl (2′OMe) modification at the 2′ sugar position throughout the sequence and a phosphorothioate (PS) backbone. The DJ-1 SSO was designed to target the 3′ splice site of DJ-1 E6 with the following sequence: 5′-GCC AAC AGA GCA GUA GGA CCU AAG-3′. Control SSO was synthesized using the following sequence: 5′- UGC AUU CGC CCU CUU AAU GGG GA-3′. To deliver SSOs into cells, SK-N-SH cells were seeded in 6-well plates (2.5 × 105 cells/well) and transfected with 1 μg of SSO using PolyMag reagent (OZ Bioscience, CA, USA) according to the manufacturer's instructions.
All sequence-specific oligonucleotides (SSOs) were purchased from Bioneer (Daejeon, Korea). The SSOs were synthesized with 2′-O-methyl (2′OMe) modification at the 2′ sugar position throughout the sequence and a phosphorothioate (PS) backbone. The DJ-1 SSO was designed to target the 3′ splice site of DJ-1 E6 with the following sequence: 5′-GCC AAC AGA GCA GUA GGA CCU AAG-3′. Control SSO was synthesized using the following sequence: 5′- UGC AUU CGC CCU CUU AAU GGG GA-3′. To deliver SSOs into cells, SK-N-SH cells were seeded in 6-well plates (2.5 × 105 cells/well) and transfected with 1 μg of SSO using PolyMag reagent (OZ Bioscience, CA, USA) according to the manufacturer's instructions.